New frontiers in meningococcal vaccines

References

• Rosenstein NE, Perkins BA, Stephens DS et al. Meningococcal disease. N. Engl. J. Med.344(18), 1378–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch. Dis. Child.88(7), 601–607 (2003).
   PubMed Web of Science ®Google Scholar
• Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics123(3), e502–e509 (2010).
   Google Scholar
• Virji M. Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat. Rev. Microbiol.7(4), 274–286 (2009).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.54(7), 1–21 (2005).
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine27(Suppl. 2), B51–B63 (2009).
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee statement (ACS). Can. Commun. Dis. Rep.35(ACS-3), 1–40 (2009).
   PubMedGoogle Scholar
• Harrison LH, Pass MA, Mendelsohn AB et al. Invasive meningococcal disease in adolescents and young adults. JAMA286(6), 694–699 (2001).
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev.19(1), 142–164 (2006).
   PubMed Web of Science ®Google Scholar
• Stephens DS. Conquering the meningococcus. FEMS Microbiol. Rev.31(1), 3–14 (2007).
   PubMed Web of Science ®Google Scholar
• LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine27(Suppl. 2), B13–B19 (2009).
   Web of Science ®Google Scholar
• Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg.96(3), 242–249 (2002).
   PubMed Web of Science ®Google Scholar
• Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis.191(8), 1263–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect.99(3), 591–601 (1987).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease – population biology and evolution. Vaccine27(Suppl. 2), B64–B70 (2009).
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J. Health Popul. Nutr.22(3), 275–285 (2004).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect. Dis.7(12), 797–803 (2007).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197(5), 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Jones GR, Williams JN, Christodoulides M et al. Lack of immunity in university students before an outbreak of serogroup C meningococcal infection. J. Infect. Dis.181(3), 1172–1175 (2000).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359(9320), 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol.53(9), 821–832 (2004).
   PubMed Web of Science ®Google Scholar
• Glitza IC, Ehrhard I, Müller-Pebody B et al. Longitudinal study of meningococcal carrier rates in teenagers. Int. J. Hyg. Environ. Health211(3–4), 263–272 (2008).
   PubMed Web of Science ®Google Scholar
• Wu HM, Harcourt BH, Hatcher CP et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N. Engl. J. Med.360(9), 886–892 (2009).
   PubMed Web of Science ®Google Scholar
• Imrey PB, Jackson LA, Ludwinski PH et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J. Clin. Microbiol.33(12), 3133–3137 (1995).
   PubMed Web of Science ®Google Scholar
• Mayer L. Immunologic methods for diagnosis of infections by Gram-negative cocci. Manual of Clinical Laboratory Immunology, 5th Edition. Rose NR, de Macario EC, Folds JD et al. (Eds). ASM Press, Washington, DC, USA, 473 (1997).
   Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med.362(16), 1511–1520 (2010).
   PubMed Web of Science ®Google Scholar
• Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet356(9248), 2159 (2000).
   PubMed Web of Science ®Google Scholar
• Bertherat E, Yada A, Djingarey MH, Koumare B. First major epidemic caused by Neisseria meningitidis serogroup W135 in Africa? Med. Trop. (Mars.)62(3), 301–304 French (2002).
   PubMedGoogle Scholar
• Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol. Rev.28, 3–26 (2006).
   PubMed Web of Science ®Google Scholar
• Tyler KT. Chapter 28: a history of bacterial meningitis. Handb. Clin. Neurol.95, 417–433 (2009).
   Google Scholar
• Brundage JF, Ryan MA, Feighner BH et al. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964–1998. Clin. Infect. Dis.35(11), 1376–1381 (2002).
   PubMed Web of Science ®Google Scholar
• Bose A, Coen P, Tully J, Viner R, Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet361(9358), 675–676 (2003).
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA292(20), 2491–2494 (2004).
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, García M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23(32), 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J.25(1), 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine27(Suppl. 2), B20–B29 (2009).
   PubMed Web of Science ®Google Scholar
• Martínez AI, Domínguez A, Oviedo M et al. Epidemiología de la enfermedad meningocócica en Cataluña antes y después de la vacunación frente al serogrupo C. Rev. Esp. Salud Publica83(5), 725–735 (2009).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines8(7), 851–861 (2009).
   PubMed Web of Science ®Google Scholar
• Okoko BJ, Idoko OT, Adegbola RA. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine27(14), 2023–2029 (2009).
   PubMed Web of Science ®Google Scholar
• Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR58(37), 1042–1043 (2009).
   PubMedGoogle Scholar
• National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2009. MMWR59(32), 1018–1023 (2010).
   PubMedGoogle Scholar
• Recommended immunization schedules for persons aged 0 through 18 years – United States, 2011. MMWR60(5), 1–4 (2011).
   PubMedGoogle Scholar
• CDC. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR60, 72–76 (2011).
   PubMedGoogle Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23(17–18), 2202–2205 (2005).
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7–2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol.13(4), 486–491 (2006).
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine24(22), 4692–4700 (2006).
   PubMed Web of Science ®Google Scholar
• Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis.165(Suppl. 1), S49–S52 (1992).
   PubMed Web of Science ®Google Scholar
• Peltola H, Mäkelä H, Käyhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med.297(13), 686–691 (1977).
   PubMed Web of Science ®Google Scholar
• Law BJ, Rosenberg T, MacDonald NE et al. Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community. Pediatr. Infect. Dis. J.17(10), 860–864 (1998).
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Tappero JW, Plikaytis BD et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect. Immun.66(6), 2453–2459 (1998).
   PubMed Web of Science ®Google Scholar
• Borrow R, Richmond P, Kaczmarski EB et al. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine. FEMS Immunol. Med. Microbiol.28(1), 79–85 (2000).
   PubMedGoogle Scholar
• Vergnano S, Heath P. Neisseria meningitidis serogroup A vaccines: an overview. Expert Rev. Vaccines2(4), 571–582 (2003).
   PubMedGoogle Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccine. Am. J. Epidemiol.162(1), 89–100 (2005).
   PubMed Web of Science ®Google Scholar
• Mohle-Boetani JC, Ajello G, Breneman E et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J.12(7), 589–593 (1993).
   PubMed Web of Science ®Google Scholar
• Bisgard KM, Kao A, Leake J et al. Haemophilus influenza invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg. Infect. Dis.4(2), 229–237 (1998).
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin. Vaccine Immunol.17(3), 325–334 (2010).
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol.17(5), 840–847 (2010).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect. Dis.6(10), 616–617; author reply 617–618 (2006).
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin. Vaccine Immunol.17(1), 154–159 (2010).
   PubMed Web of Science ®Google Scholar
• Perrett KP, Winter AP, Kibwana E et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999–2000 and response to a booster: a Phase 4 clinical trial. Clin. Infect. Dis.50(12), 1601–1610 (2010).
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis.50(2), 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4 months schedule with a fourth dose at 12–18 months of age. Hum. Vaccin.6(8), 640–651 (2010).
   PubMed Web of Science ®Google Scholar
• Hodgson A, Forgor AA, Chandramohan D et al. A Phase II, randomized study on an investigational DTPw–HBV/Hib–MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS ONE3(5), e2159 (2008).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Towne DW, Gotschlich EC, Schneerson R. “Love’s labours lost”: failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet350(9081), 880–882 (1997).
   PubMed Web of Science ®Google Scholar
• LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine25(Suppl. 1), A97–A100 (2007).
   PubMed Web of Science ®Google Scholar
• Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet361(9372), 1902–1904 (2003).
   PubMed Web of Science ®Google Scholar
• Kshirsagar N, Mur N, Thatte U et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine25(Suppl. 1), A101–A107 (2007).
   PubMed Web of Science ®Google Scholar
• Bash MC, Sow S, Okoko B et al. Human complement bactericidal activity following vaccination in a Phase 2 safety and immunogenicity study of a new meningococcal A conjugate vaccine in healthy African toddlers. Programs and Abstracts of the 16th International Pathogenic Neisseria Conference. Rotterdam, Netherlands, 7–12 September 2008 (Abstract P223).
   Google Scholar
• Mocca B, Sow S, Akinsola A et al. Human complement bactericidal activity in a Phase 2 safety and immunogenicity study following vaccination with a new meningococcal A conjugate vaccine in healthy Africans living in sub-Saharan Africa. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract P198).
   Google Scholar
• LaForce FM, Djingarey M, Tevi-Benissan C. Introduction of a new Group A meningococcal conjugate vaccine (MenAfriVac) in the African meningitis belt. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract OM39).
   Google Scholar
• Clark TA, Kristiansen PA, Diomandé F et al. Risk factors and epidemiology of Neisseria meningitidis carriage among 1–29 year-olds in one urban and two rural districts in Burkina Faso, 2009. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract P043).
   Google Scholar
• Kristiansen PA, Diomandé F, Wei SC et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin. Vaccine Immunol.18(3), 435–443 (2011).
   PubMed Web of Science ®Google Scholar
• Delrieu I, Yaro S, Ouédraogo-Traoré R et al. Emergence of Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso before introduction of a monovalent meningococcal conjugate vaccine against serogroup A. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract OM11).
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun.72(4), 2088–2100 (2004).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet322(8346), 355–357 (1983).
   Google Scholar
• Howitz M, Krause TG, Simonsen JB et al. Lack of association between group B meningococcal disease and autoimmune disease. Clin. Infect. Dis.45(10), 1327–1334 (2007).
   PubMed Web of Science ®Google Scholar
• Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine22(9–10), 1087–1096 (2004).
   PubMed Web of Science ®Google Scholar
• Milagres LG, Ramos SR, Sacchi CT et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun.62(10), 4419–4424 (1994).
   PubMed Web of Science ®Google Scholar
• Martin SL, Borrow R, van der Ley P et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine18(23), 2476–2481 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Høiby EA, Bjune G et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand.92, 323–333 (1998).
   PubMedGoogle Scholar
• Wong SH, Lennon DR, Jackson CM et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J.28(5), 385–390 (2009).
   PubMed Web of Science ®Google Scholar
• Song J, Minetti CA, Blake MS et al. Meningococcal PorA/C1, a channel that combines high conductance and high selectivity. Biophys. J.76(2), 804–813 (1999).
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338(8775), 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14(2), 195–210 (1991).
   PubMedGoogle Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340(8827), 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine13(9), 821–829 (1995).
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O’Hallahan J et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23(17–18), 2191–2196 (2005).
   PubMed Web of Science ®Google Scholar
• Pace D, Cuschieri P, Galea Debono A, Attard-Montalto S. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines. Vaccine26(47), 5952–5956 (2008).
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine23(17–18), 2023–2406 (2005).
   Web of Science ®Google Scholar
• Baart GJ, de Jong G, Philippi M et al. Scale-up for bulk production of vaccine against meningococcal disease. Vaccine25(34), 6399–6408 (2007).
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25(13), 2491–2496 (2007).
   PubMed Web of Science ®Google Scholar
• Tondella ML, Popovic T, Rosenstein NE et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol.38(9), 3323–3328 (2000).
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Whitney AM, Popovic T et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J. Infect. Dis.182(4), 1169–1176 (2000).
   PubMed Web of Science ®Google Scholar
• Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun.75(11), 5434–5442 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett JS, Bentley SD, Vernikos GS et al. Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020–006. BMC Genomics11, 652 (2010).
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol.16(8), 1113–1120 (2009).
   PubMedGoogle Scholar
• Evans CM, Pratt CB, Matheson M et al. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin. Infect. Dis.52(1), 70–77 (2011).
   PubMed Web of Science ®Google Scholar
• Verheul AF, Boons GJ, Van der Marel GA et al. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect. Immun.59(10), 3566–3573 (1991).
   PubMed Web of Science ®Google Scholar
• Weynants V, Denoël P, Devos N et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun.77(5), 2084–2093 (2009).
   PubMed Web of Science ®Google Scholar
• Verheul AF, Van Gaans JA, Wiertz EJ et al. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect. Immun.61(1), 187–196 (1993).
   PubMed Web of Science ®Google Scholar
• Gu XX, Tsai CM. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide–protein conjugates. Infect. Immun.61(5), 1873–1880 (1993).
   PubMed Web of Science ®Google Scholar
• Cox AD, Zou W, Gidney MA et al. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine23(43), 5045–5054 (2005).
   PubMed Web of Science ®Google Scholar
• Bonvehí P, Boutriau D, Casellas J et al. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin. Vaccine Immunol.17(9), 1460–1466 (2010).
   PubMedGoogle Scholar
• Lissolo L, Maitre-Wilmotte G, Dumas P et al. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun.63(3), 884–890 (1995).
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen DA, Davies HA, Borriello SP. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine12(6), 535–541 (1994).
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Høiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun.63(12), 4642–4652 (1995).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195(11), 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med.185(7), 1173–1183 (1997).
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197(6), 789–799 (2003).
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen DA, Stevenson P, Griffiths E et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect. Immun.62(7), 2984–2990 (1994).
   PubMed Web of Science ®Google Scholar
• Rokbi B, Renauld-Mongenie G, Mignon M et al. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect. Immun.68(9), 4938–4947 (2000).
   PubMed Web of Science ®Google Scholar
• Harrison OB, Maiden MC, Rokbi B. Distribution of transferrin binding protein B gene (tbpB) variants among Neisseria species. BMC Microbiol.8, 66 (2008).
   PubMed Web of Science ®Google Scholar
• Renauld-Mongénie G, Poncet D, Mignon M et al. Role of transferrin receptor from a Neisseria meningitidis tbpB isotype II strain in human transferrin binding and virulence. Infect. Immun.72(6), 3461–3470 (2004).
   PubMed Web of Science ®Google Scholar
• Pettersson A, Kortekaas J, Weynants VE et al. Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB. Vaccine24(17), 3545–3557 (2006).
   PubMed Web of Science ®Google Scholar
• Black JR, Dyer DW, Thompson MK et al. Human immune response to iron-repressible outer membrane proteins of Neisseria meningitidis. Infect. Immun.54(3), 710–713 (1986).
   PubMed Web of Science ®Google Scholar
• Dyer DW, West EP, McKenna W et al. A pleiotropic iron-uptake mutant of Neisseria meningitidis lacks a 70-kilodalton iron-regulated protein. Infect. Immun.56(4), 977–983 (1988).
   PubMed Web of Science ®Google Scholar
• Kortekaas J, Pettersson A, van der Biezen J et al. Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine25(1), 72–84 (2007).
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA et al. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun.72(10), 5955–5962 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology149(Pt 7), 1849–1858 (2003).
   PubMed Web of Science ®Google Scholar
• Claus H, Elias J, Meinhardt C, Frosch M, Vogel U. Deletion of the meningococcal fetA gene used for antigen sequence typing of invasive and commensal isolates from Germany: frequencies and mechanisms. J. Clin. Microbiol.45(9), 2960–2964 (2007).
   PubMed Web of Science ®Google Scholar
• Marsh JW, O’Leary MM, Shutt KA, Harrison LH. Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates. J. Clin. Microbiol.45(4), 1333–1335 (2007).
   PubMed Web of Science ®Google Scholar
• Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis.7(4), 504–510 (1985).
   PubMedGoogle Scholar
• Olyhoek AJ, Sarkari J, Bopp M et al. Cloning and expression in Escherichia coli of opc, the gene for an unusual class 5 outer membrane protein from Neisseria meningitidis (meningococci/surface antigen). Microb. Pathog.11(4), 249–257 (1991).
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Høiby EA, Wedege E et al. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis.167(5), 1065–1073 (1993).
   PubMed Web of Science ®Google Scholar
• Musacchio A, Carmenate T, Delgado M, González S. Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Vaccine15(6–7), 751–758 (1997).
   PubMed Web of Science ®Google Scholar
• Cunha CS, Griffiths NJ, Murillo I et al. Neisseria meningitidis Opc invasin binds to the cytoskeletal protein α-actinin. Cell Microbiol.11(3), 389–405 (2009).
   PubMed Web of Science ®Google Scholar
• Kawula TH, Aho EL, Barritt DS, Klapper DG, Cannon JG. Reversible phase variation of expression of Neisseria meningitidis class 5 outer membrane proteins and their relationship to gonococcal proteins II. Infect. Immun.56(2), 380–386 (1988).
   PubMed Web of Science ®Google Scholar
• Seiler A, Reinhardt R, Sarkari J et al. Allelic polymorphism and site-specific recombination in the opc locus of Neisseria meningitidis. Mol. Microbiol.19(4), 841–856 (1996).
   PubMed Web of Science ®Google Scholar
• Litt DJ, Savino S, Beddek A et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis.190(8), 1488–1497 (2004).
   PubMed Web of Science ®Google Scholar
• Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect. Immun.69(6), 3809–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Stork M, Bos MP, Jongerius I et al. An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog.6(7), e1000969 (2010).
   PubMed Web of Science ®Google Scholar
• Capecchi B, Adu-Bobie J, Di Marcello F et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol.55(3), 687–698 (2005).
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129(6), 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Mölling P, Olcén P. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine27(42), 5755–5759 (2009a).
   PubMed Web of Science ®Google Scholar
• Norheim G, Aseffa A, Yassin MA et al. Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin. Vaccine Immunol.15(5), 863–871 (2008).
   PubMedGoogle Scholar
• Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev. Vaccines9(10), 1203–1217 (2010).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA et al. NadA diversity and carriage in Neisseria meningitidis. Infect. Immun.72(7), 4217–4223 (2004).
   PubMed Web of Science ®Google Scholar
• Jansen KU, Emini EA, Anderson AS et al. Estimating effectiveness for Neisseria meningitidis serogroup B (MnB) vaccine candidates composed of non-serogroup specific antigens. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract VW03).
   Google Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol.47(11), 3577–3585 (2009).
   PubMed Web of Science ®Google Scholar
• Wang X, Cohn A, Comanducci M et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) (In Press).
   Google Scholar
• Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis.200(3), 379–389 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Hedberg ST, Mölling P et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine27(10), 1579–1584 (2009).
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA107(45), 19490–19495 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog.6(7), e1001027 (2010).
   PubMed Web of Science ®Google Scholar
• Laarman A, Milder F, van Strijp J, Rooijakkers S. Complement inhibition by Gram-positive pathogens: molecular mechanisms and therapeutic implications. J. Mol. Med.88(2), 115–120 (2010).
   PubMed Web of Science ®Google Scholar
• Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun.67(11), 5664–5675 (1999).
   PubMed Web of Science ®Google Scholar
• Bernfield L, Fletcher L, Howell A et al. Identification of a novel vaccine candidate for group B Neisseria meningitidis. Programs and Abstracts of the 13th International Pathogenic Neisseria Conference. Oslo, Norway, 1–6 September 2002.
   Google Scholar
• McNeil LK, Murphy E, Zhao XJ et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine27(25–26), 3417–3421 (2009).
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177(1), 501–510 (2006).
   PubMed Web of Science ®Google Scholar
• Ala’aldeen DA, Flint M, Oldfield NJ et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine28(48), 7667–7675 (2010).
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine28(9), 2122–2129 (2010).
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine28(37), 6086–6093 (2010).
   PubMed Web of Science ®Google Scholar
• Jones T, McNeil L, Harris S et al. Adult sera generated after immunization with a bivalent rFHBP vaccine demonstrated serum bactericidal activity against a broad panel of N. meningitidis serogroup B clinical isolates. Programs and Abstracts of the Seventh World Congress on Vaccines, Immunisation and Immunotherapy. Berlin, Germany, 26–28 May 2010 (Abstract S5–S7).
   Google Scholar
• Keiser PB, Miller LB, Biggs-Cicatelli S, Zollinger WD. Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis. Vaccine27(49), 6809–6813 (2009).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine28(31), 5057–5067 (2010).
   PubMed Web of Science ®Google Scholar
• Danve B, Lissolo L, Guinet F et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. Presented at: Eleventh International Pathogenic Neisseria Conference. Nice, France, 1998.
   Google Scholar
• Halperin SA, Langley JM, Smith B et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine25(3), 450–457 (2007).
   PubMed Web of Science ®Google Scholar
• Arora A. World Vaccine Congress. Expert Rev. Vaccines8(2), 135–138 (2009).
   PubMedGoogle Scholar
• Richmond P, Marshall H, Sheldon E et al. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract VW04).
   Google Scholar
• Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis.51(10), 1127–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Brunelli B, Del Tordello E, Palumbo E et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine29(5), 1072–1018 (2010).
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J.29(11), e71–e79 (2010).
   Web of Science ®Google Scholar
• Dull PM, Pizza M, Toneatto D et al. Early clinical development of a novel, multicomponent meningococcal serogroup B vaccine (4CMenB). Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–14 September 2010 (Abstract VW01).
   Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29(7), 1413–1420 (2011).
   PubMed Web of Science ®Google Scholar
• Keiser PB, Gibbs BT, Coster TS et al. A Phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine28(43), 6970–6976 (2010).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7–2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol.14(1), 65–73 (2007).
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine27(Suppl. 2), B3–B12 (2009).
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zlotnick GW, Camposano E et al. Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis. Presented at: 11th EMGM Meeting. Ljubljana, Slovenija, 18–20 May 2011.
   Google Scholar